相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存:
50
- 英文名:
SCR7 (DNA ligase IV抑制剂)
- 保质期:
一年
- 供应商:
上海再康生物科技有限公司
- 保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
- 规格:
10mM;5mg;25mg
化学信息:
| 化学名 | 5-(benzylideneamino)-6-[(E)-benzylideneamino]-2-sulfanylidene-1H-pyrimidin-4-one | |
| 简称 | SCR7 | |
| 别名 | CS-3903, AK174235, BC600700, QC-11823, X3557 | |
| 中文名 | N/A | |
| 化学式 | C18H14N4OS | |
| 分子量 | 334.4 | |
| CAS号 | 1533426-72-0 | |
| 纯度 | 98% | |
| 溶剂/溶解度 | Water<1mg/ml; DMSO45mg/ml; Ethanol<1mg/ml | |
| 溶液配制 | 5mg加入1.5ml DMSO,或者每3.34mg加入1ml DMSO,配制成10mM溶液。SF1136-10mM用DMSO配制。 |
生物信息:
| 产品描述 | SCR7 is a molecule that inhibits joining of DSBs in cell-free repair system; inhibits NHEJ (nonhomologous end-joining) in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. | ||||
| 信号通路 | Others | ||||
| 靶点 | Ligase IV inhibitor | NHEJ inhibitor | - | - | - |
| IC50 | ~40nM | ~40nM | - | - | - |
| 体外研究 | SCR7 does not induce DSBs directly to the genome and is Ligase IV dependent. Besides, upon incubation of oligomeric dsDNA or supercoiled plasmid DNA with increasing concentrations of SCR7, there was no evidence for DNA breaks. Accumulation of DSBs leads to cell death upon SCR7 treatment with a dose-dependent decrease in cell proliferation of MCF7, A549, and HeLa with an IC50 of 40, 34 and 44μM, respectively, which was further confirmed by DIC imaging in MCF7. T47D, A2780 and HT1080 were also sensitive to SCR7, with an IC50 of 8.5, 120, and 10μM, respectively. SCR7 encapsulated micelles (ES) were also characterized by small-angle neutron scattering (SANS). Encapsulated SCR7 treatment resulted in accumulation of DNA breaks within the cells, resulting in cell cycle arrest at G1 phase and activation of apoptosis. | ||||
| 体内研究 | SCR7 treatment (10mg/kg, six doses) significantly reduced breast adenocarcinoma-induced tumor in mice. Untreated tumor animals survived only for 52 days, whereas treated animals exhibited ~4-fold increase in lifespan. Treatment with SCR7 resulted in regression of tumors with no obvious adverse effects. In addition, HPLC analysis of serum following administration of SCR7 into mice (20mg/kg) showed bioavailability of 114μg/ml and a t1/2 of 1hr. | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献,再康生物并不保证其有效性):
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
1. Srivastava M, et al. Cell. 2012 Dec 21, 151(7), 1474-87.
包装清单:
| 产品编号 | 产品名称 | 包装 |
| ZK-1136-10mM | SCR7 (DNA ligase IV抑制剂) | 10mM×0.2ml |
| ZK-1136-5mg | SCR7 (DNA ligase IV抑制剂) | 5mg |
| ZK-1136-25mg | SCR7 (DNA ligase IV抑制剂) | 25mg |
| — | 说 明 书 | 1份 |
保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。
使用说明:
1.收到产品后请立即按照 说 明 书 推荐的条件保存。使用前可以在2,000-10,000g离心数秒,以使液体或粉末充分沉降至管底后再开盖使用。
2.对于10mM溶液,可直接稀释使用。对于固体,请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
3.具体的最佳工作浓度请参考本 说 明 书 中的体外、体内研究结果或其它相关文献,或者根据实验目的,以及所培养的特定细胞和组织,通过实验进行摸索和优化。
4.不同实验动物依据体表面积的等效剂量转换
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验; 2)DNM T3a、DNM T3b从头甲基转移酶, 它们可甲基化CPG, 使其半甲基化, 继而全甲基化。从头甲基转移酶可能参与细胞生长分化调控, 其中DNM T3b在肿瘤基因甲基化中起重要作用。三、 相关图解四、 DNMT的抑制剂Decitabine:Decitabine是一种DNA甲基化的有效抑制剂,作用于HL-60和KG1a细胞时,IC50分别为100 ng/mL和1 ng/mL。Lomeguatrib:Lomeguatrib是一种有效的O6-alkylguanine-DNA
Ligation of DNA with T4 DNA Ligase
recombination and DNA synthesis. DNA ligase from E. coli is a polypeptide with a molecular weight of 74,000 and is NAD-dependent. T4 DNA ligase is the product of gene 30 of the T4 phage, has a molecular weight of 68,000, and is ATP-dependent. Both enzymes
Joining RNA Molecules with T4 DNA Ligase
Researchers interested in studying RNA structure and function or RNA-protein interactions are increasingly using site-specifically modified RNAs to probe sites of interest (1 ). In addition to expanding the repertoire of functional groups
技术资料暂无技术资料 索取技术资料






